Your browser doesn't support javascript.
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2.
Krasemann, Susanne; Haferkamp, Undine; Pfefferle, Susanne; Woo, Marcel S; Heinrich, Fabian; Schweizer, Michaela; Appelt-Menzel, Antje; Cubukova, Alevtina; Barenberg, Janica; Leu, Jennifer; Hartmann, Kristin; Thies, Edda; Littau, Jessica Lisa; Sepulveda-Falla, Diego; Zhang, Liang; Ton, Kathy; Liang, Yan; Matschke, Jakob; Ricklefs, Franz; Sauvigny, Thomas; Sperhake, Jan; Fitzek, Antonia; Gerhartl, Anna; Brachner, Andreas; Geiger, Nina; König, Eva-Maria; Bodem, Jochen; Franzenburg, Sören; Franke, Andre; Moese, Stefan; Müller, Franz-Josef; Geisslinger, Gerd; Claussen, Carsten; Kannt, Aimo; Zaliani, Andrea; Gribbon, Philip; Ondruschka, Benjamin; Neuhaus, Winfried; Friese, Manuel A; Glatzel, Markus; Pless, Ole.
  • Krasemann S; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Experimental Pathology Core Facility, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Electronic address: s.krasemann@uke.de.
  • Haferkamp U; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Pfefferle S; Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Bernhard Nocht Institute, Leibniz Institute for Tropical Medicine, 20359 Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Borstel-Lübeck-Riems, 2
  • Woo MS; Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Heinrich F; Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Schweizer M; Morphology and Electron Microscopy Core Facility, Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Appelt-Menzel A; University Hospital Würzburg, Chair Tissue Engineering and Regenerative Medicine (TERM), 97070 Würzburg, Germany; Fraunhofer Institute for Silicate Research (ISC), Translational Center Regenerative Therapies (TLC-RT), 97070 Würzburg, Germany.
  • Cubukova A; Fraunhofer Institute for Silicate Research (ISC), Translational Center Regenerative Therapies (TLC-RT), 97070 Würzburg, Germany.
  • Barenberg J; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Leu J; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Hartmann K; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; Experimental Pathology Core Facility, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Thies E; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Littau JL; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Sepulveda-Falla D; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Zhang L; Nanostring Technologies, Seattle, WA 98109, USA.
  • Ton K; Nanostring Technologies, Seattle, WA 98109, USA.
  • Liang Y; Nanostring Technologies, Seattle, WA 98109, USA.
  • Matschke J; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Ricklefs F; Department for Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Sauvigny T; Department for Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Sperhake J; Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Fitzek A; Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Gerhartl A; AIT-Austrian Institute of Technology GmbH, 1210 Wien, Austria.
  • Brachner A; AIT-Austrian Institute of Technology GmbH, 1210 Wien, Austria.
  • Geiger N; University Würzburg, Institute of Virology and Immunobiology, 97078 Würzburg, Germany.
  • König EM; University Würzburg, Institute of Virology and Immunobiology, 97078 Würzburg, Germany.
  • Bodem J; University Würzburg, Institute of Virology and Immunobiology, 97078 Würzburg, Germany.
  • Franzenburg S; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, 24105 Kiel, Germany.
  • Franke A; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, 24105 Kiel, Germany.
  • Moese S; Neurimmune AG, 8952 Schlieren, Switzerland.
  • Müller FJ; Zentrum für Integrative Psychiatrie (ZIP) GmbH, Universitätsklinikum Schleswig-Holstein, 24105 Kiel, Germany.
  • Geisslinger G; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), 60596 Frankfurt am Main, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Claussen C; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Kannt A; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), 60596 Frankfurt am Main, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Zaliani A; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Gribbon P; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany.
  • Ondruschka B; Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Neuhaus W; AIT-Austrian Institute of Technology GmbH, 1210 Wien, Austria.
  • Friese MA; Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Glatzel M; Institute for Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Pless O; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, 22525 Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), 60596 Frankfurt am Main, Germany. Electronic address: ole.pless@itmp.fraunhofer.de.
Stem Cell Reports ; 17(2): 307-320, 2022 02 08.
Article in English | MEDLINE | ID: covidwho-1712991
ABSTRACT
Neurological complications are common in COVID-19. Although SARS-CoV-2 has been detected in patients' brain tissues, its entry routes and resulting consequences are not well understood. Here, we show a pronounced upregulation of interferon signaling pathways of the neurovascular unit in fatal COVID-19. By investigating the susceptibility of human induced pluripotent stem cell (hiPSC)-derived brain capillary endothelial-like cells (BCECs) to SARS-CoV-2 infection, we found that BCECs were infected and recapitulated transcriptional changes detected in vivo. While BCECs were not compromised in their paracellular tightness, we found SARS-CoV-2 in the basolateral compartment in transwell assays after apical infection, suggesting active replication and transcellular transport of virus across the blood-brain barrier (BBB) in vitro. Moreover, entry of SARS-CoV-2 into BCECs could be reduced by anti-spike-, anti-angiotensin-converting enzyme 2 (ACE2)-, and anti-neuropilin-1 (NRP1)-specific antibodies or the transmembrane protease serine subtype 2 (TMPRSS2) inhibitor nafamostat. Together, our data provide strong support for SARS-CoV-2 brain entry across the BBB resulting in increased interferon signaling.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood-Brain Barrier / Central Nervous System / Virus Internalization / SARS-CoV-2 Limits: Humans Language: English Journal: Stem Cell Reports Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood-Brain Barrier / Central Nervous System / Virus Internalization / SARS-CoV-2 Limits: Humans Language: English Journal: Stem Cell Reports Year: 2022 Document Type: Article